Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3839840 · 1 trial · 1 indication
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| LY3839840 (Part A) | EXPERIMENTAL | Single ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Cohort 1-3 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Cohort 4 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Optional Cohort 5 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally pending data from Cohort 4 |
| LY3839840 (Part C) | EXPERIMENTAL | Single and multiple dose of LY3839840 administered orally in Chinese participants. |
| LY3839840 (Part D) | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally in Japanese participants. |
| Placebo (Parts A-D) | PLACEBO_COMPARATOR | Placebo administered orally. |
| Midazolam (Part E) | EXPERIMENTAL | Midazolam substrate alone or with LY3839840 administered orally |
| Name | Type | Description |
|---|---|---|
| LY3839840 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
| Midazolam | DRUG | Administered orally |
Inclusion Criteria: Healthy men and women. Women may only be included if they are of nonchildbearing potential For Part C: • Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grand...
LY3839840 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. It is not yet approved and remains under clinical investigation.
LY3839840 is being studied for use in healthy participants. The Phase 1 trial, NCT06153355, is a first-in-human study designed to evaluate the drug in healthy volunteers. The specific condition it is intended to treat has not been disclosed, as the study focuses on healthy individuals.
LY3839840 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker LLY. The company is conducting clinical research on this investigational drug, which is currently in Phase 1 development.
LY3839840 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is being studied in a first-in-human trial involving healthy participants to assess its safety and tolerability.
LY3839840 has one completed clinical trial, NCT06153355, titled "A First-In-Human Study of LY3839840 in Healthy Participants." This Phase 1 trial enrolled 140 participants in the United States, was randomized, double-blind, and placebo-controlled. The study included healthy volunteers aged 18 years and older.